Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FISONS MEETS WITH FDA COMMISSIONER YOUNG TO DISCUSS PNEUMOPENT NDA

Executive Summary

FISONS MEETS WITH FDA COMMISSIONER YOUNG TO DISCUSS PNEUMOPENT NDA and the future of the product in the wake of a Treatment IND approval for Lyphomed's aerosolized Pentam. Participants in the June 1 meeting included Young, FDA Drugs and Biologics Center Directors Carl Peck and Paul Parkman, and FDA Deputy Commissioner James Benson, as well as Fisons President Stephen Attwood, Memorial Sloan-Kettering Infectious Disease Service Chief Donald Armstrong, MD, and Covington and Burling attorney Peter Barton Hutt. Fisons presented data from its U.S. double-blind active control trials with its aerosolized pentamidine product Pneumopent to the FDA group in an attempt to demonstrate efficacy and possible advantages over Pentam. Fisons said that it has not yet filed the U.S. trial data, which will complete the NDA submission. Fisons has been trying to find an angle around the seven-year market exclusivity that Lyphomed likely will receive. The burden of proof will apparently be on Fisons to show that sufficient differences exist between Pneumopent and Pentam in order to consider them different drugs. The major difference between the two products is their nebulizer systems -- Pentam uses the Respirgard II with a compressor while Pneumopent uses the hand held atomizer FISONeb. Another potential selling point is that Fisons has proposed to market its product at 50% of the Lyphomed price , which is approximately $ 100 per 300 mg vial. There are indications that FDA is in a quandary about what to do with the Fisons product once it approves Pentam, possibly in the next couple of weeks. The agency is still considering Fisons' Treatment IND request and has asked the company to recheck some of the datapoints from its Canadian Pneumopent trials. The FDA request should take several weeks, Fisons said. Agency officials recently met with Congressional Health Subcommittee Chairman Henry Waxman's (D-Calif.) staff to discuss the orphan status of aerosolized pentamidine. Reportedly, Waxman staffers were interested in FDA estimates of the numbers of patients who would benefit from treatment with aerosolized pentamidine. FDAers attending the meeting included FDA Office of Drug Evaluation II Director James Bilstad, MD, Orphan Products Director Marlene Haffner, MD, General Counsel Thomas Scarlett, and Legislative Affairs staffer JoAnne Marrone.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

OM013658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel